ID   ACV1B_HUMAN             Reviewed;         505 AA.
AC   P36896; B7Z5L8; B7Z5W5; Q15479; Q15480; Q15481; Q15482;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Activin receptor type-1B;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor type IB;
DE            Short=ACTR-IB;
DE   AltName: Full=Activin receptor-like kinase 4;
DE            Short=ALK-4;
DE   AltName: Full=Serine/threonine-protein kinase receptor R2;
DE            Short=SKR2;
DE   Flags: Precursor;
GN   Name=ACVR1B; Synonyms=ACVRLK4, ALK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), IDENTIFICATION IN A ACTIVIN
RP   RECEPTOR COMPLEX, ACTIVIN-BINDING, AND FUNCTION.
RC   TISSUE=Kidney;
RX   PubMed=8196624; DOI=10.1128/MCB.14.6.3810;
RA   Carcamo J., Weis F.M., Ventura F., Wieser R., Wrana J.L., Attisano L.,
RA   Massague J.;
RT   "Type I receptors specify growth-inhibitory and transcriptional
RT   responses to transforming growth factor beta and activin.";
RL   Mol. Cell. Biol. 14:3810-3821(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 2 AND 3), AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Liver;
RX   PubMed=8058741; DOI=10.1073/pnas.91.17.7957;
RA   Xu J., Matsuzaki K., McKeehan K., Wang F., Kan M., McKeehan W.L.;
RT   "Genomic structure and cloned cDNAs predict that four variants in the
RT   kinase domain of serine/threonine kinase receptors arise by
RT   alternative splicing and poly(A) addition.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:7957-7961(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 5).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH ACVR2B, PHOSPHORYLATION BY ACVR2B, DOMAIN GS, AND
RP   MUTAGENESIS OF THR-206.
RX   PubMed=8622651; DOI=10.1128/MCB.16.3.1066;
RA   Attisano L., Wrana J.L., Montalvo E., Massague J.;
RT   "Activation of signalling by the activin receptor complex.";
RL   Mol. Cell. Biol. 16:1066-1073(1996).
RN   [9]
RP   SUBUNIT, AND FUNCTION.
RX   PubMed=9032295; DOI=10.1128/MCB.17.3.1682;
RA   Lebrun J.J., Vale W.W.;
RT   "Activin and inhibin have antagonistic effects on ligand-dependent
RT   heteromerization of the type I and type II activin receptors and human
RT   erythroid differentiation.";
RL   Mol. Cell. Biol. 17:1682-1691(1997).
RN   [10]
RP   INTERACTION WITH SMAD2; SMAD3 AND SMAD7, AND FUNCTION.
RX   PubMed=9892009; DOI=10.1210/mend.13.1.0218;
RA   Lebrun J.J., Takabe K., Chen Y., Vale W.;
RT   "Roles of pathway-specific and inhibitory Smads in activin receptor
RT   signaling.";
RL   Mol. Endocrinol. 13:15-23(1999).
RN   [11]
RP   INTERACTION WITH IGSF1, AND ENZYME REGULATION.
RX   PubMed=11266516; DOI=10.1210/mend.15.4.0616;
RA   Chapman S.C., Woodruff T.K.;
RT   "Modulation of activin signal transduction by inhibin B and inhibin-
RT   binding protein (INhBP).";
RL   Mol. Endocrinol. 15:668-679(2001).
RN   [12]
RP   PHOSPHORYLATION, AND INTERACTION WITH SMAD7.
RX   PubMed=12023024; DOI=10.1016/S0014-5793(02)02718-7;
RA   Liu X., Nagarajan R.P., Vale W., Chen Y.;
RT   "Phosphorylation regulation of the interaction between Smad7 and
RT   activin type I receptor.";
RL   FEBS Lett. 519:93-98(2002).
RN   [13]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=12364468; DOI=10.1210/jc.2002-020527;
RA   Danila D.C., Zhang X., Zhou Y., Haidar J.N., Klibanski A.;
RT   "Overexpression of wild-type activin receptor alk4-1 restores activin
RT   antiproliferative effects in human pituitary tumor cells.";
RL   J. Clin. Endocrinol. Metab. 87:4741-4746(2002).
RN   [14]
RP   INTERACTION WITH TDGF1, AND ENZYME REGULATION.
RX   PubMed=11909953; DOI=10.1128/MCB.22.8.2586-2597.2002;
RA   Bianco C., Adkins H.B., Wechselberger C., Seno M., Normanno N.,
RA   De Luca A., Sun Y., Khan N., Kenney N., Ebert A., Williams K.P.,
RA   Sanicola M., Salomon D.S.;
RT   "Cripto-1 activates nodal- and ALK4-dependent and -independent
RT   signaling pathways in mammary epithelial Cells.";
RL   Mol. Cell. Biol. 22:2586-2597(2002).
RN   [15]
RP   PHOSPHORYLATION AT TYR-380.
RX   PubMed=12112843;
RX   DOI=10.1002/1615-9861(200206)2:6<642::AID-PROT642>3.0.CO;2-I;
RA   Maguire P.B., Wynne K.J., Harney D.F., O'Donoghue N.M., Stephens G.,
RA   Fitzgerald D.J.;
RT   "Identification of the phosphotyrosine proteome from thrombin
RT   activated platelets.";
RL   Proteomics 2:642-648(2002).
RN   [16]
RP   FUNCTION.
RX   PubMed=12639945; DOI=10.1210/en.2002-220978;
RA   Mukasa C., Nomura M., Tanaka T., Tanaka K., Nishi Y., Okabe T.,
RA   Goto K., Yanase T., Nawata H.;
RT   "Activin signaling through type IB activin receptor stimulates
RT   aromatase activity in the ovarian granulosa cell-like human granulosa
RT   (KGN) cells.";
RL   Endocrinology 144:1603-1611(2003).
RN   [17]
RP   MUTAGENESIS OF LEU-40; ILE-70; VAL-73; LEU-75 AND PRO-77, AND
RP   ACTIVIN-BINDING.
RX   PubMed=12665502; DOI=10.1074/jbc.M302015200;
RA   Harrison C.A., Gray P.C., Koerber S.C., Fischer W., Vale W.;
RT   "Identification of a functional binding site for activin on the type I
RT   receptor ALK4.";
RL   J. Biol. Chem. 278:21129-21135(2003).
RN   [18]
RP   INTERACTION WITH FKBP1A AND SMAD7, AND UBIQUITINATION.
RX   PubMed=16720724; DOI=10.1677/jme.1.01966;
RA   Yamaguchi T., Kurisaki A., Yamakawa N., Minakuchi K., Sugino H.;
RT   "FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin
RT   type I receptor.";
RL   J. Mol. Endocrinol. 36:569-579(2006).
RN   [19]
RP   FUNCTION, AND AUTOPHOSPHORYLATION.
RX   PubMed=18039968; DOI=10.1242/dev.000026;
RA   Esguerra C.V., Nelles L., Vermeire L., Ibrahimi A., Crawford A.D.,
RA   Derua R., Janssens E., Waelkens E., Carmeliet P., Collen D.,
RA   Huylebroeck D.;
RT   "Ttrap is an essential modulator of Smad3-dependent Nodal signaling
RT   during zebrafish gastrulation and left-right axis determination.";
RL   Development 134:4381-4393(2007).
RN   [20]
RP   FUNCTION.
RX   PubMed=20226172; DOI=10.1016/j.bbrc.2010.03.039;
RA   Suzuki K., Kobayashi T., Funatsu O., Morita A., Ikekita M.;
RT   "Activin A induces neuronal differentiation and survival via ALK4 in a
RT   SMAD-independent manner in a subpopulation of human neuroblastomas.";
RL   Biochem. Biophys. Res. Commun. 394:639-645(2010).
RN   [21]
RP   UBIQUITINATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [22]
RP   INVOLVEMENT IN SYSTEMIC SCLEROSIS.
RX   PubMed=21377836; DOI=10.1016/j.jaut.2010.09.004;
RA   Takagi K., Kawaguchi Y., Kawamoto M., Ota Y., Tochimoto A., Gono T.,
RA   Katsumata Y., Takagi M., Hara M., Yamanaka H.;
RT   "Activation of the activin A-ALK-Smad pathway in systemic sclerosis.";
RL   J. Autoimmun. 36:181-188(2011).
RN   [23]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-146, AND VARIANT [LARGE SCALE
RP   ANALYSIS] HIS-478 (ISOFORM 3).
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase activin type-1
CC       receptor forming an activin receptor complex with activin receptor
CC       type-2 (ACVR2A or ACVR2B). Transduces the activin signal from the
CC       cell surface to the cytoplasm and is thus regulating a many
CC       physiological and pathological processes including neuronal
CC       differentiation and neuronal survival, hair follicle development
CC       and cycling, FSH production by the pituitary gland, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. Activin is also thought to have a paracrine or
CC       autocrine role in follicular development in the ovary. Within the
CC       receptor complex, type-2 receptors (ACVR2A and/or ACVR2B) act as a
CC       primary activin receptors whereas the type-1 receptors like ACVR1B
CC       act as downstream transducers of activin signals. Activin binds to
CC       type-2 receptor at the plasma membrane and activates its serine-
CC       threonine kinase. The activated receptor type-2 then
CC       phosphorylates and activates the type-1 receptor such as ACVR1B.
CC       Once activated, the type-1 receptor binds and phosphorylates the
CC       SMAD proteins SMAD2 and SMAD3, on serine residues of the C-
CC       terminal tail. Soon after their association with the activin
CC       receptor and subsequent phosphorylation, SMAD2 and SMAD3 are
CC       released into the cytoplasm where they interact with the common
CC       partner SMAD4. This SMAD complex translocates into the nucleus
CC       where it mediates activin-induced transcription. Inhibitory SMAD7,
CC       which is recruited to ACVR1B through FKBP1A, can prevent the
CC       association of SMAD2 and SMAD3 with the activin receptor complex,
CC       thereby blocking the activin signal. Activin signal transduction
CC       is also antagonized by the binding to the receptor of inhibin-B
CC       via the IGSF1 inhibin coreceptor. ACVR1B also phosphorylates TDP2.
CC       {ECO:0000269|PubMed:12364468, ECO:0000269|PubMed:12639945,
CC       ECO:0000269|PubMed:18039968, ECO:0000269|PubMed:20226172,
CC       ECO:0000269|PubMed:8196624, ECO:0000269|PubMed:9032295,
CC       ECO:0000269|PubMed:9892009}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activin receptor type-2 (ACVR2A or ACVR2B)
CC       activates the type-1 receptor through phosphorylation of its
CC       regulatory GS domain. {ECO:0000269|PubMed:11266516,
CC       ECO:0000269|PubMed:11909953}.
CC   -!- SUBUNIT: Forms an activin receptor complex with activin receptor
CC       type-2 (ACVR2A or ACVR2B). Interacts with TDP2 (By similarity).
CC       Interacts with AIP1, FKBP1A, IGSF1, TDGF1, SMAD2, SMAD3 and SMAD7.
CC       {ECO:0000250, ECO:0000269|PubMed:11266516,
CC       ECO:0000269|PubMed:11909953, ECO:0000269|PubMed:12023024,
CC       ECO:0000269|PubMed:16720724, ECO:0000269|PubMed:8196624,
CC       ECO:0000269|PubMed:8622651, ECO:0000269|PubMed:9032295,
CC       ECO:0000269|PubMed:9892009}.
CC   -!- INTERACTION:
CC       P62942:FKBP1A; NbExp=2; IntAct=EBI-1384128, EBI-1027571;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1384128, EBI-352572;
CC       O15105:SMAD7; NbExp=2; IntAct=EBI-1384128, EBI-3861591;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=SKR2-1;
CC         IsoId=P36896-1; Sequence=Displayed;
CC       Name=2; Synonyms=SKR2-2;
CC         IsoId=P36896-2; Sequence=VSP_004954;
CC       Name=3; Synonyms=SKR2-3;
CC         IsoId=P36896-3; Sequence=VSP_004953;
CC         Note=Variant in position: 478:R->H.;
CC       Name=4;
CC         IsoId=P36896-4; Sequence=VSP_041842;
CC       Name=5;
CC         IsoId=P36896-5; Sequence=VSP_041841;
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues, most strongly in
CC       kidney, pancreas, brain, lung, and liver.
CC   -!- DOMAIN: The GS domain is a 30-amino-acid sequence adjacent to the
CC       N-terminal boundary of the kinase domain and highly conserved in
CC       all other known type-1 receptors but not in type-2 receptors. The
CC       GS domain is the site of activation through phosphorylation by the
CC       II receptors. {ECO:0000269|PubMed:8622651}.
CC   -!- PTM: Autophosphorylated. Phosphorylated by activin receptor type-2
CC       (ACVR2A or ACVR2B) in response to activin-binding at serine and
CC       threonine residues in the GS domain. Phosphorylation of ACVR1B by
CC       activin receptor type-2 regulates association with SMAD7.
CC       {ECO:0000269|PubMed:12023024, ECO:0000269|PubMed:12112843,
CC       ECO:0000269|PubMed:12364468, ECO:0000269|PubMed:8622651}.
CC   -!- PTM: Ubiquitinated. Level of ubiquitination is regulated by the
CC       SMAD7-SMURF1 complex.
CC   -!- PTM: Ubiquitinated.
CC   -!- DISEASE: Note=ACVRIB is abundantly expressed in systemic sclerosis
CC       patient fibroblasts and production of collagen is also induced by
CC       activin-A/INHBA. This suggests that the activin/ACRV1B signaling
CC       mechanism is involved in systemic sclerosis.
CC       {ECO:0000269|PubMed:21377836}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22536; CAA80258.1; -; mRNA.
DR   EMBL; U14722; AAA50246.1; -; mRNA.
DR   EMBL; L10125; AAA60555.1; -; mRNA.
DR   EMBL; L10126; AAA60556.1; -; mRNA.
DR   EMBL; L31848; AAA53349.1; -; Genomic_DNA.
DR   EMBL; L31848; AAA53350.1; -; Genomic_DNA.
DR   EMBL; L31848; AAA53351.1; -; Genomic_DNA.
DR   EMBL; BT007072; AAP35735.1; -; mRNA.
DR   EMBL; AK299120; BAH12954.1; -; mRNA.
DR   EMBL; AK299496; BAH13051.1; -; mRNA.
DR   EMBL; AC025259; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000254; AAH00254.1; -; mRNA.
DR   EMBL; BC040531; AAH40531.1; -; mRNA.
DR   CCDS; CCDS44893.2; -. [P36896-5]
DR   CCDS; CCDS44894.2; -. [P36896-4]
DR   CCDS; CCDS8816.1; -. [P36896-1]
DR   PIR; I38859; I38859.
DR   PIR; I80182; I80182.
DR   PIR; I80183; I80183.
DR   RefSeq; NP_004293.1; NM_004302.4. [P36896-1]
DR   RefSeq; NP_064732.3; NM_020327.3. [P36896-5]
DR   RefSeq; NP_064733.3; NM_020328.3. [P36896-4]
DR   UniGene; Hs.438918; -.
DR   ProteinModelPortal; P36896; -.
DR   BioGrid; 106606; 45.
DR   DIP; DIP-427N; -.
DR   IntAct; P36896; 13.
DR   BindingDB; P36896; -.
DR   ChEMBL; CHEMBL5310; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   GuidetoPHARMACOLOGY; 1787; -.
DR   iPTMnet; P36896; -.
DR   PhosphoSitePlus; P36896; -.
DR   BioMuta; ACVR1B; -.
DR   DMDM; 547775; -.
DR   MaxQB; P36896; -.
DR   PeptideAtlas; P36896; -.
DR   PRIDE; P36896; -.
DR   DNASU; 91; -.
DR   Ensembl; ENST00000257963; ENSP00000257963; ENSG00000135503. [P36896-1]
DR   Ensembl; ENST00000415850; ENSP00000397550; ENSG00000135503. [P36896-3]
DR   Ensembl; ENST00000426655; ENSP00000390477; ENSG00000135503. [P36896-2]
DR   Ensembl; ENST00000541224; ENSP00000442656; ENSG00000135503. [P36896-4]
DR   Ensembl; ENST00000542485; ENSP00000442885; ENSG00000135503. [P36896-5]
DR   GeneID; 91; -.
DR   KEGG; hsa:91; -.
DR   UCSC; uc001rzl.4; human. [P36896-1]
DR   CTD; 91; -.
DR   DisGeNET; 91; -.
DR   GeneCards; ACVR1B; -.
DR   HGNC; HGNC:172; ACVR1B.
DR   HPA; CAB026126; -.
DR   HPA; HPA063761; -.
DR   MalaCards; ACVR1B; -.
DR   MIM; 601300; gene.
DR   neXtProt; NX_P36896; -.
DR   OpenTargets; ENSG00000135503; -.
DR   PharmGKB; PA24493; -.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36896; -.
DR   KO; K13567; -.
DR   OMA; QCACTSC; -.
DR   OrthoDB; EOG091G0BIU; -.
DR   PhylomeDB; P36896; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-1433617; Regulation of signaling by NODAL.
DR   Reactome; R-HSA-1502540; Signaling by Activin.
DR   SignaLink; P36896; -.
DR   SIGNOR; P36896; -.
DR   GeneWiki; ACVR1B; -.
DR   GenomeRNAi; 91; -.
DR   PRO; PR:P36896; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000135503; -.
DR   CleanEx; HS_ACVR1B; -.
DR   ExpressionAtlas; P36896; baseline and differential.
DR   Genevisible; P36896; HS.
DR   GO; GO:0048179; C:activin receptor complex; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:HGNC.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:HGNC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0048185; F:activin binding; IEA:Ensembl.
DR   GO; GO:0016361; F:activin receptor activity, type I; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0034711; F:inhibin binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:HGNC.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; NAS:BHF-UCL.
DR   GO; GO:0032924; P:activin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007417; P:central nervous system development; IEA:Ensembl.
DR   GO; GO:0046545; P:development of primary female sexual characteristics; IEA:Ensembl.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IDA:HGNC.
DR   GO; GO:0001942; P:hair follicle development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:HGNC.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0038092; P:nodal signaling pathway; IGI:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032927; P:positive regulation of activin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:HGNC.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:1901165; P:positive regulation of trophoblast cell migration; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC.
DR   GO; GO:0007178; P:transmembrane receptor protein serine/threonine kinase signaling pathway; TAS:ProtInc.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Transferase; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     23       {ECO:0000255}.
FT   CHAIN        24    505       Activin receptor type-1B.
FT                                /FTId=PRO_0000024417.
FT   TOPO_DOM     24    126       Extracellular. {ECO:0000255}.
FT   TRANSMEM    127    149       Helical. {ECO:0000255}.
FT   TOPO_DOM    150    505       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      177    206       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      207    497       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     213    221       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    335    335       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     234    234       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     380    380       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12112843}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1     52       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041841.
FT   VAR_SEQ     271    271       D -> ADCSFLTLPWEVVMVSAAPKLRSLRLQYKGGRGRAR
FT                                FLFPLN (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041842.
FT   VAR_SEQ     422    505       VHEEYQLPYYDLVPSDPSIEEMRKVVCDQKLRPNIPNWWQS
FT                                YEALRVMGKMMRECWYANGAARLTALRIKKTLSQLSVQEDV
FT                                KI -> TFLFCLCSYLPFQDAGSPKAVLLPPFFLQPVGCLL
FT                                PEPESSFKVAIKGVEVAVLRVRLFFRDQFVE (in
FT                                isoform 3). {ECO:0000303|PubMed:8058741}.
FT                                /FTId=VSP_004953.
FT   VAR_SEQ     465    505       ALRVMGKMMRECWYANGAARLTALRIKKTLSQLSVQEDVKI
FT                                -> VRSWPPAAFPSA (in isoform 2).
FT                                {ECO:0000303|PubMed:8058741}.
FT                                /FTId=VSP_004954.
FT   VARIANT     146    146       F -> L (in dbSNP:rs34488074).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041406.
FT   VARIANT     408    408       L -> V (in dbSNP:rs928906).
FT                                /FTId=VAR_011716.
FT   MUTAGEN      40     40       L->A: Increases binding to activin.
FT                                {ECO:0000269|PubMed:12665502}.
FT   MUTAGEN      70     70       I->A: Decreases binding to activin.
FT                                {ECO:0000269|PubMed:12665502}.
FT   MUTAGEN      73     73       V->A: Increases binding to activin.
FT                                {ECO:0000269|PubMed:12665502}.
FT   MUTAGEN      75     75       L->A: Decreases binding to activin.
FT                                {ECO:0000269|PubMed:12665502}.
FT   MUTAGEN      77     77       P->A: Decreases binding to activin.
FT                                {ECO:0000269|PubMed:12665502}.
FT   MUTAGEN     206    206       T->V: Leads to constitutive activation.
FT                                {ECO:0000269|PubMed:8622651}.
FT   CONFLICT     56     56       I -> F (in Ref. 3; AAA60555/AAA60556).
FT                                {ECO:0000305}.
FT   CONFLICT    222    223       WR -> MA (in Ref. 3; AAA60555/AAA60556).
FT                                {ECO:0000305}.
SQ   SEQUENCE   505 AA;  56807 MW;  40A6C65CAA4C7573 CRC64;
     MAESAGASSF FPLVVLLLAG SGGSGPRGVQ ALLCACTSCL QANYTCETDG ACMVSIFNLD
     GMEHHVRTCI PKVELVPAGK PFYCLSSEDL RNTHCCYTDY CNRIDLRVPS GHLKEPEHPS
     MWGPVELVGI IAGPVFLLFL IIIIVFLVIN YHQRVYHNRQ RLDMEDPSCE MCLSKDKTLQ
     DLVYDLSTSG SGSGLPLFVQ RTVARTIVLQ EIIGKGRFGE VWRGRWRGGD VAVKIFSSRE
     ERSWFREAEI YQTVMLRHEN ILGFIAADNK DNGTWTQLWL VSDYHEHGSL FDYLNRYTVT
     IEGMIKLALS AASGLAHLHM EIVGTQGKPG IAHRDLKSKN ILVKKNGMCA IADLGLAVRH
     DAVTDTIDIA PNQRVGTKRY MAPEVLDETI NMKHFDSFKC ADIYALGLVY WEIARRCNSG
     GVHEEYQLPY YDLVPSDPSI EEMRKVVCDQ KLRPNIPNWW QSYEALRVMG KMMRECWYAN
     GAARLTALRI KKTLSQLSVQ EDVKI
//
